8-K: Aprea Therapeutics Reports Promising Progress in Cancer Drug Development and Secures $16 Million in Financing

Aprea Therapeutics announced positive financial results for 2023, progress in clinical trials for its ATR and WEE1 inhibitors, and a $16 million private placement.

Summary

• Aprea Therapeutics reported its financial results for the fourth quarter and full year of 2023, along with a business update.
• The company's lead ATR inhibitor, ATRN-119, is on track to complete dose escalation by the end of 2024, with initial efficacy data expected in the second half of 2024.
• Aprea received FDA clearance for its IND application for APR-1051, a WEE1 inhibitor, and plans to initiate a Phase 1 clinical trial in the first half of 2024.
• As of December 31, 2023, Aprea had $21.6 million in cash and cash equivalents.
• A private placement in March 2024 raised approximately $16 million in gross proceeds.
• The company believes its current cash, combined with the recent financing, will fund operations into the third quarter of 2025.
• The operating loss for the year ended December 31, 2023, was $15.5 million, compared to $113.4 million in 2022, which included a $76 million charge for acquired in-process research and development.
• Research and development expenses for 2023 were $7.6 million, down from $16.4 million in 2022.
• General and administrative expenses for 2023 were $8.4 million, compared to $21.0 million in 2022.
• The net loss for 2023 was $14.3 million, or $3.95 per basic share, compared to a net loss of $112.7 million, or $67.99 per basic share, in 2022.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and successful fundraising, but also acknowledges the inherent risks and financial losses associated with a clinical-stage biopharmaceutical company.

Positives

• Aprea has made significant progress in its clinical programs, with both ATRN-119 and APR-1051 advancing through clinical trials.
• The company has secured sufficient funding to continue operations into the third quarter of 2025.
• ATRN-119 has demonstrated a favorable safety profile in early trials.
• APR-1051 has shown promising preclinical data, suggesting it could be a best-in-class WEE1 inhibitor.
• The company has a strong intellectual property portfolio with multiple patents protecting its lead molecules.

Negatives

• Aprea reported an operating loss of $15.5 million for the year ended December 31, 2023.
• The company has a history of net losses, with a net loss of $14.3 million in 2023.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.

Risks

• The success and timing of clinical trials for ATRN-119 and APR-1051 are subject to risks and uncertainties.
• The company's ability to raise additional capital may restrict operations or require relinquishing rights to technologies or product candidates.
• There is a risk that the company's product candidates may not achieve market acceptance.
• The company's understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results may not be indicative of final results.
• The company is subject to legislative, regulatory, political, and economic developments not within its control.

Future Outlook

Aprea expects to complete the dose escalation phase of the ATRN-119 trial by the end of 2024, initiate the Phase 1 trial for APR-1051 in the first half of 2024, and have sufficient cash to fund operations into the third quarter of 2025. The company also anticipates selecting a lead molecule for a third synthetic lethality program in the second quarter of 2024.

Management Comments

• Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, stated that the company had a very productive 2023 with significant progress across its pipeline.
• Dr. Gilad also mentioned that the recent private placement financing provides the capital to fund both lead programs through meaningful clinical milestones.
• Dr. Gilad expressed the company's mission to be a global leader in synthetic lethality and create value for shareholders.

Industry Context

Aprea is operating in the competitive field of precision oncology, focusing on synthetic lethality. The company's approach of targeting the DNA Damage Response (DDR) pathway with ATR and WEE1 inhibitors aligns with current trends in cancer drug development. The company is competing with other companies developing similar inhibitors, such as AstraZeneca, Bayer, and Zentalis, but is attempting to differentiate itself with its macrocyclic ATR inhibitor and highly selective WEE1 inhibitor.

Comparison to Industry Standards

• Aprea's ATRN-119 is a macrocyclic inhibitor, which is a differentiated approach compared to first-generation acyclic ATR inhibitors like AstraZeneca's AZD6738 and Bayer's BAY1895344.
• The company claims that ATRN-119 has a potentially better toxicity profile than other ATR inhibitors, which have shown hematological toxicities in clinical trials.
• Aprea's APR-1051 is designed to be more selective than other WEE1 inhibitors like AstraZeneca's Adavosertib (AZD-1775) and Zentalis' Azenosetrib (ZN-c3), with lower off-target activity against PLK1, PLK2, and PLK3.
• The company's preclinical data suggests that APR-1051 has favorable pharmacokinetic properties and causes little anemia, which are potential advantages over other WEE1 inhibitors.

Stakeholder Impact

• Shareholders may be positively impacted by the company's progress in clinical trials and successful fundraising.
• Employees may be positively impacted by the company's continued operations and growth.
• Cancer patients may benefit from the development of new and potentially more effective cancer therapies.
• Investors may be interested in the company's potential for future growth and value creation.

Next Steps

• Aprea will complete the dose escalation phase of the ATRN-119 trial.
• The company will initiate the Phase 1 clinical trial for APR-1051.
• Aprea will select a lead molecule for a third synthetic lethality program.
• The company will present a more comprehensive dataset from Part 1 of the ATRN-119 study at the AACR annual meeting in April 2024.

Key Dates

Keywords

Aprea Therapeutics, ATRN-119, APR-1051, ATR inhibitor, WEE1 inhibitor, synthetic lethality, cancer therapeutics, clinical trials, precision oncology, DNA Damage Response, DDR, oncology